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OBJECTIVES: Serrated polyposis syndrome (SPS) is a complex disorder with a high risk of colorectal cancer for which
the germline factors remain largely unknown. Here, we combined whole-exome sequencing (WES) and
linkage studies in families with multiple members affected by SPS to identify candidate genes
harboring rare variants with higher penetrance effects.
METHODS: Thirty-nine affected subjects from 16 extended SPS families underwent WES. Genome-wide
linkage analysis was performed under linear and exponential models. The contribution of rare
coding variants selected to be highly pathogenic was assessed using the gene-based segregation
test.
RESULTS: A significant linkage peak was identified on chromosome 3p25.2-p22.3 (maxSNP 5 rs2293787;
LODlinear 5 2.311, LODexp 5 2.11), which logarithm of the odds (LOD) score increased after fine
mapping for the samemarker (maxSNP5 rs2293787; LODlinear5 2.4, LODexp5 2.25). This linkage
signal was replicated in 10 independent sets of random markers from this locus. To assess the
contribution of rare variants predicted to be pathogenic, we performed a family-based segregation test
with 11 rare variants predicted to be deleterious from 10 genes under the linkage intervals. This
analysis showed significant segregation of rare variants with SPS in CAPT7, TMEM43, NGLY1, and
FBLN2 genes (weighted P value > 0.007).
DISCUSSION: Protein network analysis suggested FBLN2 as the most plausible candidate genes for germline SPS
predisposition. Etiologic rare variants implicated in disease predisposition may be identified by
combining traditional linkage with WES data. This powerful approach was effective for the
identification of a new candidate gene for hereditary SPS.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most frequent neoplasms
and an important cause of mortality in the developed world.
Approximately 5% of the population develops CRC, and this
figure is expected to rise as life expectancy increases. For 2018,
over 1.8 million new CRC cases and 881,000 related-deaths were
estimated to occur in the world (1).
Most CRCs progress through the adenoma-carcinoma se-
quence (2). The malignant transformation of conventional ade-
nomas was considered for decades to be the single mechanism
underlying the genesis of CRC. Serrated polyps, also previously
known as hyperplastic polyps, were first described in the early
seventies (3). These polyps exhibit a serrated architecture with
infolding of colonocytes in the lumen of the crypts showing
a stellate or star-like appearance on cross section and a saw-
toothed form in a longitudinal section. Nowadays, they are also
considered CRC precursor lesions and an alternative pathway to
CRC (4).
Serrated polyposis syndrome (SPS) is a disease with unknown
inherited genetic basis characterized by the presence of multiple
and/or large serrated polyps in the colon and a high risk of CRC.
Although previously considered an uncommon entity, recent
evidence estimates that is one of the most frequent polyposis
syndromes (5). The following criteria were established by the
World Health Organization in 2010 (6) to help identifying this
clinical entity(1): at least 5 serrated polyps proximal to the sig-
moid colon with 2 or more of these being .10 mm (2), any
number of serrated polyps proximal to the sigmoid colon in an
individual who has a first-degree relative with serrated polyposis,
or (3).20 serrated polyps of any size, but distributed throughout
the colon. Accordingly, SPS is a very heterogeneous entity, with
different phenotypes. Very recently, a new set of SPS criteria has
been published, which do not consider any longer criterion
number 2 (7).
Smoking and obesity have been associated as environmental
factors with an increased risk of developing serrated polyps (4).
Actually, most patients with SPS are diagnosed over the age of 60
years, with no significant family history of CRC or SPS. Family
aggregation of SPS has been described in,5%of cases. Regarding
SPS germline predisposition, both dominant and recessive
models have been suggested, although the hereditary genetic basis
for this clinical entity remains mostly unidentified. Rarely, ser-
rated polyposis has been found concomitantly with hereditary
forms caused by mutations in APC andMUTYH (8,9). The only
proposed gene so far for germline predisposition to SPS has been
RNF43 although with controversy (10,11).
Recently, there have been several efforts to identify additional
genetic factors that predispose to CRC using linkage analysis.
Such studies in affected families were able to pinpoint chromo-
somal regions of interest such as 9q22 and 3q22, but no clear CRC
predisposition genes were identified after screening for in-
teresting candidates within these areas (12,13). A linkage analysis
study specifically for SPS concluded that 2q32.2-q33.3 was the
most likely region to contain a predisposition gene for this dis-
ease (14).
On the other hand, next-generation sequencing (NGS) tech-
nologies have been recently established as a new approach to
identify genes involved in disease predisposition (15), and whole-
exome sequencing (WES) directed to genome coding regions
(exons) has become the most fruitful application of NGS in
translational research (16). Several studies usingWES on familial
CRC cohorts have proposed several candidate genes for germline
predisposition but also have evidenced that the number of can-
didate variants is still too high and should be reduced by other
means (17). Also, linkage analysis conducted with common
polymorphisms present in the already available WES data has
been postulated as a cost-effective strategy to tackle regions of
linkage and focus on genes located on those areas (18,19).
In the present study, we combined WES and linkage analysis
in 16 families with unaffiliated SPS aggregation. Available se-
quencing data from 39 patients were used to identify the more
plausible candidate genes in the regions of positive linkage. By
doing so, we aim to help identifying the rare, high-penetrance
germline predisposition cause in these families and to facilitate
genetic counseling and prevention strategies.
MATERIALS AND METHODS
Study participants
Sixteen families with at least 2 affected relatives with unaffiliated
SPS/CRC aggregation compatible with an autosomal dominant
pattern of inheritance were selected (Figure 1). The included
patients with SPS fulfilled at least 1 of the World Health Orga-
nization (WHO) SPS criteria, except for 3 patients (in families 3,
10, and 11) with CRC but without information regarding the SPS
criteria. Accordingly, 39 patients from these 16 SPS families were
included. Their clinical characteristics are summarized in Table 1.
This study was approved by the institutional ethics committee,
and written informed consent was obtained in all cases.
WES
The entire cohort of 39 patients underwent germline WES sim-
ilarly to previous reported studies performed by our research
group in familial CRC (20–22). Briefly, WES was characterized
using the HiSeq2000 platform (Illumina, San Diego, CA) and
SureSelectXTHuman All Exon V5 for exon enrichment (Agilent,
Santa Clara, CA). Indexed libraries were pooled and massively
parallel sequenced using a paired-end 2 3 75 bp read length
protocol. Mean coverage was .953 in all samples, and 51 Mb
was the target size that required about 4 Gb of sequencing per
sample. Burrows-Wheeler Aligner was used for read mapping to
the human reference genome (build hs37d5, based on NCBI
GRCh37) (23). Polymerase chain reaction duplicates were dis-
carded using theMarkDuplicates tool fromPicard, and then indel
realignment and base quality score recalibration were performed
with theGenomeAnalysis Toolkit. TheHaplotypeCallerGenome
Analysis Toolkit tool was used for variant calling (24).
Linkage analysis procedures
Genotypes were called from aligned WES reads using SAMtools
pileup and filtered to include haplotype-informative markers
(HapMap CEU population) using LINKDATAGEN (25). WES-
derived genotypes were used to confirm familial relationships by
pairwise identity by descent usingPLINK (26), andZ0, Z1, andZ2
valueswere obtained.All genotyped-derived genetic relationships
were consistent with the clinical records.
A linkage study was performed using 5,726 WES-derived
single nucleotide polymorphisms (SNPs) from 22 autosomal
chromosomes (N 5 5,566 SNPs) and the X chromosome
(N 5 160 SNPs) across all 16 families. Nonparametric linkage
analyses were performed using the “all” statistic implemented in
Merlin, under the Kong and Cox linear (logarithm of the odds
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Figure 1. Pedigree structure of the 16 SPSmultiplex and extended families examined in our study. Males are indicated with squares, females with circles,
and diagnosis is shownby dark shading (full, patients diagnosedwith SPS, white right quarter, patients diagnosedwith CRC; left quarter, patients diagnosed
with adenoma; half, patients diagnosedwith any other type of cancer detailed in the figure legend; unshaded, unaffected individuals or unknown). Patients
analyzed by WES are indicated by an asterisk, and all subjects with DNA available are underlined. CRC, colorectal cancer; SPS, serrated polyposis
syndrome; WES, whole-exome sequencing.
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Table 1. Clinical characteristics of 39 patients from 16 SPS families included in the reported study
FAM-ID Ind-ID Diagnosis SPS criteriaa Sex Age at onset (y.o.)
CRC family
history
1 AA3519 SPS 1,3 M 58 2
1 AA3520 SPS 2 F 62 2
2 AA3521 SPS 1,3 M 62 1
2 AA3522 SPS 2 M 59 1
3 AA3523 CRC 2 M 32 1
3 AA3524 SPS 3 F 64 1
4 AA3525 SPS 3 M 58 1
4 AA3526 SPS 2 F 53 1
5 AA3527 SPS 3 F 22 2
5 AA3528 SPS 2 M 20 2
6 AA3529 SPS 3 F 61 1
6 AA3530 SPS 2 F 53 1
7 AA3531 SPS/CRC 1,3 F 57 1
7 AA3532 SPS 2 M 56 1
8 AA3534 SPS 2 M 65 2
8 AA3533 SPS 3 M 62 2
9 AA3537 SPS 3 M 64 1
9 AA3536 SPS 2 F 70 1
9 AA3535 SPS/CRC 2,3 F 65 1
10 AA3541 SPS 1,3 F 40 1
10 AA3538 CRC 2 F 58 1
10 AA3539 SPS 2 M 60 1
10 AA3540 SPS 2 F 53 1
11 AA3559 SPS 2 F 39 1
11 AA3560 SPS 1 F 46 1
11 AA3561 SPS 2 F 38 1
11 AA3562 SPS 2 M 44 1
11 AA3563 CRC 2 F 54 1
11 AA3564 SPS 2 M 48 1
12 AA3566 SPS 1,2,3 M 59 2
12 AA3565 SPS 2,3 M 55 2
13 AA3568 SPS 1,2,3 F 55 2
13 AA3567 SPS 2,3 M 59 2
14 AA3569 SPS/CRC 2,3 M 68 1
14 AA3570 SPS 2,3 M 74 1
15 AA3572 SPS 1,3 M 38 2
15 AA3571 SPS 2 M 67 2
16 AA3573 SPS 2,3 F 47 2
16 AA3574 SPS 2 M 51 2
CRC, colorectal cancer; Fam-ID, family identification number; F, female; Ind-ID, individual identification number; M, male; SPS, serrated polyposis syndrome; y.o., years
old; 1, presence of colorectal cancer in the family; -, no colorectal cancer family history.
aAll families included amember who fulfilled either criterion 1 or 3. Therefore, the newWHOSPS classification criteria will not change considering these families as having 1
member diagnosed with SPS (7).
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[LOD]) and exponential (ExLOD) models (27). All genotyped
individuals in our study were affected and, where possible, from
the most distant branches of each pedigree. Pedigree structures
and diagnoses are detailed in Figure 1. The results of the linkage
genome scan under both linear and exponential models were
plotted using the “lodplot” R package (https://cran.r-project.
org/src/contrib/Archive/lodplot).
Fine mapping of linkage peaks
AnLOD score threshold greater than 2was considered suggestive
evidence of linkage. A fine mapping study was performed in-
cluding additional polymorphic SNPs in flanking regions of
a linkage peak to increase allelic informativeness and where
intermarker interval was less than 1 cM. Three additional SNPs
with high heterozygosity in white Europeans (http://www.inter-
nationalgenome.org/) were selected in 3p25.2-p22.3 (rs13078867,
rs17016865, and rs7634752). The fine mapping linkage analysis
included 340 total markers for chromosome 3 within a 1-LOD
drop interval. Their allelic frequencies were extracted from
a Spanish control population of 629 individuals (28). After fine
mapping, the relative family contribution to the overall linkage
was computed using the –perFamily option in Merlin. Further
examination of the robustness of the linkage peak was assessed
through a replicative analysis using 10 sets of randomly selected
WES-derived markers from chromosome 3 (2,847 SNPs) that
were nonmonomorphic in the HapMap CEU population.
Rare variant selection
Different parameters were considered for variant annotation in-
cluding population frequency (1000 Genomes, Exome Variant
Server, Exome Aggregation Consortium, and Collaborative
Spanish Variant Server), functional consequences, pathogenicity,
and position (SnpEff, ANNOtate VARiation, and dbNSFP).
Variant filtering was performed with an in-house R language
pipeline, already described in previous studies (20,21). Briefly,
parameters taken into account were sequencing quality (coverage
$103 and genotype quality $50), germline allelic frequency
(#0.1% in Exome Aggregation Consortium database), internal
cohort frequency (#25%), and functional effect (truncating or
predicted disrupting missense variants). Missense pathogenicity
prediction was assessed with PhyloP (score $ 1.6), Sorting In-
tolerant fromTolerant (damaging), PolyPhen2-HVAR (probably
or possibly damaging), MutationTaster (disease causing), likeli-
hood ratio test (deleterious), and Combined Annotation De-
pendentDepletion (score$15).Missense variants predicted to be
pathogenic in a least 3 of 6 predictor tools were selected. Variants
were also visually inspected with the Integrative Genomics
Viewer and discarded if any sequencing artifact was detected (29).
Family-based association analysis for rare variants
A total of 11 rare and potentially disruptive variants regardless
their segregation status in the families from genes spanning the
detected linkage interval were included for a family-based asso-
ciation test, using the gene-based segregation test (GESE) package
implemented in R (https://cran.r-project.org/web/packages/
GESE/) (30). Segregation of rare variants was assessed including
all individuals diagnosed with SPS, CRC, or polyposis. P values
for statistical significance were calculated after 100,000 simu-
lations. Per-family weights were included in the analysis to as-
sess a relative symptom severity variable based on the number of
patients with SPS and CRC per family, earlier age at onset, and
presence of precursor lesions and other extracolonic neoplasms.
Selection of novel candidate genes for SPS
The prioritization process was completed with selection of the
putative candidate genes arising from the GESE family-based
association analysis and their interaction partners. This selection
process was performed using the Ingenuity Pathway Analysis
(IPA) software program (Ingenuity Systems Redwood City, CA),
which can identify significant networks using a build-in scientific
literature–based database (31). The associated genes with un-
adjusted P value,0.05 from the family-based analysis were used
as input for IPA and combined with well-known hereditary CRC
genes (APC, MLH1, MSH2, MSH6, PMS2, MUTYH, BMPR1A,
BMP4, PTPRJ, GALNT12, EPHB2, AXIN2, UNC5C, GREM1,
STK11, SMAD4, PTEN, KLLN, POLE, POLD1, BUB3, BUB1,
BUB1B, RNF43, ATM, PALB2, SEMA4A, RPS20, NTHL1, FAN1,
MCM9,BLM,LRP6, SMAD9,MSH3,EPCAM, SETD6, andBRF1)
and 115 cancer predisposition genes (32). Networks containing
any of the GESE genes were considered of interest.
Colon tissue expression from the Human Protein Atlas (Ge-
notype-Tissue Expression data set and protein expression) was
evaluated to consider only expressed candidate genes (reads per
kilo base per million mapped reads .1). The final candidate
variant was confirmed by Sanger sequencing (GATC Biotech,
Germany).
RESULTS
Linkage analysis
A genome-wide nonparametric linkage analysis was performed
using WES-derived genotype data from 16 families with un-
affiliated SPS aggregation (Figure 1). The highest peak LOD score
was identified on chromosome 3p25.2-p22.3 with LODlinear 5
2.311 and LODexp 5 2.11 at rs2293787 (46.484 cM) (Figure 2).
When additional markers were added to fine map the region and
reduce intermarker intervals, evidence for linkage at the 3p25.2-
p22.3 locus increased to LODlinear5 2.4 (P value5 4.4E-04) and
LODexp5 2.25 (P value5 6.4E-04)with rs2293787 remaining the
peak marker (Figure 3, see Table S1, Supplementary Digital
Content 1, http://links.lww.com/CTG/A114).
We examined the robustness of the observed linkage signal by
a replicative analysis performing linkage analysis in 10 replicate
SNP sets using randommarkers from chromosome 3 (see Figure
S1, SupplementaryDigital Content 1, http://links.lww.com/CTG/
A114). The linkage peak previously identifiedwas replicated in all
the 10 data sets with an LOD .2 under either the linear or the
exponential model or both. These results suggest that the linkage
to these regions is not being driven by a particular set of SNPs and
is robust to SNP selection. A formal permutation analysis to ex-
clude false-positive signals and to determine empirical signifi-
cancewas not possible, as all subjects were affected and permuting
the subjects’ phenotypes would be uninformative.
The SPS linkage interval, as defined by a 1-LOD drop interval,
spanned a genetic distance of 28.4 cM (3p25.2-p22.3) and
a physical interval of 20,874 Mb. Per-family linkage analysis
showed that 12 SPS families were contributing positively to the
overall LOD score at the 3p25.2-p22.3 linkage peak ranging from
an LOD score of 0.06–0.37 (see Table S2, Supplementary Digital
Content 1, http://links.lww.com/CTG/A114), with the remaining
4 families contributing onlymarginally with negative LOD scores
ranging from20.002 to 20.099.
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Family-based association analysis for variants under specific
linkage intervals
Next, we explored the possibility that rare alleles with higher
penetrance effects explained the linkage peaks at this locus. We
extracted 74 single nucleotide variants (SNVs) from WES data
within 42 protein-coding genes under the linkage peak interval
(Figure 3), and after quality control filters and more stringent
selection criteria, 11 SNVs from 10 genes were selected for seg-
regation analysis (see Table S3, Supplementary Digital Content 1,
http://links.lww.com/CTG/A114).
Then, we performed a family GESE of the 11 rare variants
using the GESE package. Allele-frequency weighted segregation
analysis revealed significant rare variant segregation with SPS in 4
genes (Table 2).
Novel candidate gene for SPS
Genes with evidence of familial segregation for rare pathogenic
variants inpatientswithCRCwere further inspectedusingaprotein-
protein network analysis (IPA) to identify the most plausible can-
didate genes from the linkage peaks involved in hereditaryCRC.We
pooled together the 4 geneswith segregating variants from theGESE
analysis with established genes for hereditary CRC (38 genes) and
germline predisposition to cancer (115 genes) to investigate specific
CRC networks. The resulting networks should contain those can-
didate genes more likely to interact with hereditary CRC and
germline cancer predisposition genes and, therefore, more likely to
be themselves better candidates for our study. The FBLN2 gene was
present in the only network produced containing at least 1 of the
GESE candidate genes (see Figure S2, Supplementary Digital Con-
tent 1, http://links.lww.com/CTG/A114). Colon tissue expression
was evaluated for this gene (RPKM 5 19), whereas the final can-
didate variant in FBLN2 (c.3145C.G, p.Pro1049Ala) was validated
in the Integrative Genomics Viewer and further confirmed by
Sanger sequencing. This rare missense variant is predicted to be
pathogenic and falls within an EGF-like calcium domain. Accord-
ingly, FBLN2was considered in our approach as the more plausible
candidate to be involved in germline predisposition to SPS.
DISCUSSION
It is considered that up to 15%–30% of all CRC tumors have
serrated polyps as their precursor lesions. These lesions are
characterized by the presence of somatic mutations in BRAF,
hypermethylation of the promoter regions of tumor suppressor
genes, and microsatellite instability (33). SPS is a heterogeneous
syndrome defined nowadays by the WHO criteria (7) that is
linked with an increased CRC risk (16%) (34). It must be noted
that the recently established new SPS criteria would not change
the classification of the individuals included in the present study,
so obtained results would not be altered.
Although smoking and obesity are linked to serrated polyps, it
is believed that germline predisposition to SPS can be also of
relevance (35). Whereas several studies have focused in germline
CRC predisposition, limited efforts have been developed seeking
for hereditary SPS genes. On the other hand, it is plausible that
some overlap at the clinical and molecular levels may exist be-
tween SPS and another clinical entity, hereditarymixed polyposis
syndrome (HMPS). HMPS is a hereditary condition associated
with an increased risk of developing polyps in the digestive tract,
most commonly in the colon and/or rectum. Polyps detected in
patients with HMPS can be of mixed histological type including
Figure 2. Results of the genome-wide linkage analysis. Nonparametric linkage analysis was performed under the linear (black line) and exponential (red
line) models in 16 multiplex/extended serrated polyposis syndrome families. Each chromosome is represented in a plot, including the X chromosome. A
linkage signal with LOD. 2 was observed at chromosome 3p25.2-p22.3 with a maximum linear LOD score at marker rs2293787 of 2.311 (linear model).
Additional markers were subsequently added to fine map this linkage peak.
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adenomatous, hyperplastic, hamartomatous/juvenile, or serrated
(35). Some linkage studies were developed in a HMPS family of
Ashkenazi descent locating positive linkage at chromosome
6q16-q21 (36). New clinical and molecular data from additional
members showed that linkage signal to be incorrect and signifi-
cant evidence was found for chromosomal region 15q13-q14
(37). In addition, a genome-wide linkage search on 32members of
2HMPS families detected positive linkage on chromosome 10q23
and found a mutation in BMPR1A in 1 family (38). Recently,
a duplication spanning the 3’ end of the SCG5 gene and a region
upstream of the GREM1 gene was found to be the mutational
event behind the HMPS positive linkage to 15q13-q14 (39).
There are very few NGS studies for SPS germline pre-
disposition. The first study was performed using WES in 20 SPS
families and identified 2 independent families with a germline
deleterious variant in RNF43 (10). Additional patients with SPS
carrying putative pathogenic variants in this same gene have been
identified by subsequent studies (40–42), although its implication
in SPS germiline predisposition is still controversial (11).
Interestingly, linkage analysis has reappeared as a successful
approach to uncover genes implicated in mendelian diseases
when used in combination with NGS (43,44). This approach has
also been recently applied in complex disorders where suscepti-
bility loci are examined for rare variants with higher penetrance
effects that are expected to segregate among patients in large
families. This combined strategy has been used in large individual
families or few combined families in some complex disorders
(45,46), but has never been applied in multiplex or extended
families with cancer predisposition.
Segregation analysis for potentially pathogenic rare variants
inherited by patients with SPS followed by a protein network
analysis identified FBLN2 as the most relevant candidate for
germline SPS predisposition, mapping to 3p25.2-p22.3. According
to the available information, the other 3 genes without interactions
with known hereditary CRC/cancer genes seem to be not linked to
SPS or CRC predisposition. CAPN7 is a member of the calpain
family. Calpains are ubiquitous, well-conserved family of calcium-
dependent, cysteine proteases. The calpain proteins are hetero-
dimers consisting of an invariant small subunit and variable large
subunits. The large subunit possesses a cysteine protease domain,
and both subunits possess calcium-binding domains. Calpains
have been implicated in neurodegenerative processes, as their ac-
tivation canbe triggered by calcium influxandoxidative stress (47).
As for TMEM43, defects in this gene are the cause of familial
arrhythmogenic right ventricular dysplasia type 5, also known as
arrhythmogenic right ventricular cardiomyopathy type 5.
Arrhythmogenic right ventricular dysplasia is an inherited disor-
der, often involving both ventricles, and is characterized by ven-
tricular tachycardia, heart failure, sudden cardiac death, and
fibrofatty replacement of cardiomyocytes. This gene contains
Table 2. Family-based association test of rare variants under the
linkage peaks
Gene SNVs (Seg-SNV) FAM-ID P value Weighted P value
CAPN7 1 (1) 14 4.00E-07 4.00E-07
TMEM43 1 (1) 7 5.19E-04 1.61E-04
NGLY1 2 (1) 7 7.10E-04 2.10E-04
FBLN2 1 (1) 15 0.01178 7.06E-03
Results of segregation analysis of 11 rare variants (SNVs) found in 39 patients
with SPS across the 16 SPS families after simulations and weight corrections.
Only significant genes (P, 0.05) are reported.
SNVs, number of SNVs regardless segregation in patients with CRC; Seg-SNV,
number of SNVs segregating in all patients with CRC in this family.
CRC, colorectal cancer; SNV, single nucleotide variant; Fam-ID, family
identification number.
Figure 3. Schematic of the linkage interval and the gene content between the proximal and distal boundaries on chromosome 3p25.2-p22.3 after fine
mapping with 3 additional single nucleotide polymorphisms. The maximum LOD score under linear and exponential models are shown at each locus. The
locations of known protein-coding genes in the linkage interval are provided in the images below, which were generated using the UCSC genome browser
(https://genome.ucsc.edu). Final candidate gene for serrated polyposis syndrome, after gene network analysis and colon gene expression evaluation, is
highlighted with a green box.
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a response element for PPAR gamma (an adipogenic transcription
factor), which may explain the fibrofatty replacement of the
myocardium, a characteristic pathological finding in ARVC (48).
Regarding the NGLY1 gene, it encodes an enzyme that catalyzes
hydrolysis of an N(4)-(acetyl-beta-D-glucosaminyl) asparagine
residue to N-acetyl-beta-D-glucosaminylamine and a peptide
containing an aspartate residue. The encoded enzyme may play
a role in the proteasome-mediated degradation of misfolded gly-
coproteins. Recessive mutations in this gene cause a congenital
disorder of deglycosylation that can include neuromotor impair-
ment, intellectual disability, and neuropathy (49). On the other
hand, FBLN2 is an extracellular matrix protein that belongs to the
fibulin family. Fibulin interactions with a variety of extracellular
ligands are believed to be critical in determining cell movement,
proliferation, and angiogenesis, assigning them an important role
in cancer development (50). Indeed, FBLN2 was previously iden-
tified as a candidate tumor suppressor gene in nasopharyngeal
carcinoma (51), whereas it was also suggested to act as a promoter
ofmalignant progression in lung adenocarcinoma (52). Recently, it
was also demonstrated to be methylated in CRC (53) and to play
a role in malignancy potential of breast cancer cells (54). Alto-
gether, it could be suggested that FBLN2 could act as a tumor
suppressor gene and, when altered, deregulate correct cell move-
ment and proliferation, and these alterations may lead to the SPS
phenotype. Accordingly, additional functional studies including
analysis of somatic alterations and germline variants in this gene
are warranted to further investigate this hypothesis.
In summary, we performed a genome-wide linkage analysis
using WES-derived genotype data from 16 multiplex and ex-
tended families with unaffiliated strong SPS aggregation and
found suggestive risk loci on chromosome 3p25.2-p22.3. Rare
variant segregation analysis and protein network analyses im-
plicated FBLN2 as a plausible candidate for germline SPS
predisposition.
It should be noted that our study has strengths and limitations.
WESdata from2ormore individuals fromeach family permitted to
embark on a linkage analysis as a novel approach to uncover pos-
sible candidates for SPS germline predisposition. WES data avail-
ability along with the strategy of using it for a traditional linkage
analysis could be considered themain strengths.On theother hand,
the lackof access to somatic tissue or informationonenvironmental
factors, the fact that WES only interrogates the coding genome, or
that RNF43 was not interrogated could be listed among the study
limitations. Also, we should be aware that replication in additional
cohorts, including targeted sequencing of large numbers of families
with SPS, and further functional studies are required to confirm this
potential candidate for SPS germline predisposition.
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